Literature DB >> 12842429

Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages.

Akhil Banerjea1, Ming-Jie Li, Gerhard Bauer, Leila Remling, Nan-Sook Lee, John Rossi, Ramesh Akkina.   

Abstract

The phenomenon of RNA interference mediated by small interfering RNAs (siRNAs) is a potent gene-silencing mechanism. A number of recent studies demonstrated inhibition of HIV-1 replication in cultured cells using this approach. To make further progress and harness this technology for HIV-1 gene therapy in a stem cell setting, in vivo studies using primary hematopoietic cells are needed. Using an HIV-based lentiviral vector we introduced an anti-Rev siRNA construct into CD34(+) hematopoietic progenitor cells. The siRNA-transduced progenitor cells were allowed to mature into macrophages in vitro and T cells in vivo in SCID-hu mouse thy/liv grafts. Phenotypically normal T cells and macrophages displaying characteristic surface markers were obtained. In vitro HIV-1 challenge of the siRNA-expressing macrophages and T cells with macrophage-tropic and T-cell-tropic HIV-1, respectively, showed marked viral resistance. These experiments demonstrate the utility of siRNAs delivered into hematopoietic stem cells via lentiviral vectors for future in vivo applications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842429     DOI: 10.1016/s1525-0016(03)00140-0

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  55 in total

Review 1.  The use of cell-delivered gene therapy for the treatment of HIV/AIDS.

Authors:  Geoff P Symonds; Helen A Johnstone; Michelle L Millington; Maureen P Boyd; Bryan P Burke; Louis R Breton
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

Review 2.  HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms.

Authors:  Atze T Das; Ben Berkhout
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-06-27       Impact factor: 6.237

3.  Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies.

Authors:  Ying Poi Liu; Monique A Vink; Jan-Tinus Westerink; Eva Ramirez de Arellano; Pavlina Konstantinova; Olivier Ter Brake; Ben Berkhout
Journal:  RNA       Date:  2010-05-24       Impact factor: 4.942

4.  Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.

Authors:  Joshua N Leonard; David V Schaffer
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV.

Authors:  Sang-Kyung Lee; Derek M Dykxhoorn; Priti Kumar; Shahin Ranjbar; Erwei Song; Laura E Maliszewski; Vanessa François-Bongarçon; Anne Goldfeld; N Manjunath Swamy; Judy Lieberman; Premlata Shankar
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

6.  Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors.

Authors:  Dong Sung An; F Xiao-Feng Qin; Vincent C Auyeung; Si Hua Mao; Sam K P Kung; David Baltimore; Irvin S Y Chen
Journal:  Mol Ther       Date:  2006-07-17       Impact factor: 11.454

Review 7.  RNAi therapeutics: principles, prospects and challenges.

Authors:  Lars Aagaard; John J Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

8.  Efficient transduction of cytotoxic and anti-HIV-1 genes by a gene-regulatable lentiviral vector.

Authors:  Yasuhiko Shinoda; Kuniko Hieda; Yoshio Koyanagi; Youichi Suzuki
Journal:  Virus Genes       Date:  2009-10       Impact factor: 2.332

Review 9.  Application of RNA interference in treating human diseases.

Authors:  S Abdolhamid Angaji; Sara Sadate Hedayati; Reihane Hosein Poor; Safoura Madani; Sanaz Samad Poor; Samin Panahi
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

Review 10.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.